{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:41:31Z","timestamp":1791103291450,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.autrev.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T06:04:50Z","timestamp":1408428290000},"page":"945-953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors"],"prefix":"10.1016","volume":"13","author":[{"given":"Maxime","family":"Samson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pu\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Devilliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mouthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.08.002_bb0005","first-page":"S49","article-title":"Clinical pictures of and therapeutic strategies for systemic vasculitides","volume":"3","author":"Guillevin","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.002_bb0010","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.lpm.2012.06.008","article-title":"How to treat systemic necrotizing vasculitides?","volume":"41","author":"Guillevin","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2014.08.002_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg\u2013Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2014.08.002_bb0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2014.08.002_bb0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg\u2013Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0035","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg\u2013Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0040","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients","volume":"62","author":"Ribi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.08.002_bb0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.autrev.2013.10.001","article-title":"Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors","volume":"13","author":"Samson","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.002_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0060","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0025-6196(11)63594-5","article-title":"Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group","volume":"72","author":"Jayne","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2014.08.002_bb0065","first-page":"671","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2014.08.002_bb0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0075","first-page":"1","article-title":"The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC\/BCR Group for ANCA Assay Standardization","volume":"159","author":"Hagen","year":"1993","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.autrev.2014.08.002_bb0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.002_bb0085","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2014.08.002_bb0090","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.autrev.2012.08.007","article-title":"Treatment of ANCA-associated vasculitides (AAV)","volume":"12","author":"Holle","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.002_bb0095","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.002_bb0100","first-page":"S315","article-title":"Efficacy of glucocorticoids to treat limited flares in ANCA-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.lpm.2013.02.069","article-title":"Treatment of systemic necrotizing vasculitides in patients \u226565years old: results of the multicenter randomized CORTAGE trial","volume":"42","author":"Pagnoux","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2014.08.002_bb0110","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2014.08.002_bb0115","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.autrev.2010.07.009","article-title":"Microscopic polyangiitis: clinical presentation","volume":"9","author":"Villiger","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.002_bb0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.08.002_bb0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0031-1279826","article-title":"Churg\u2013strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment","volume":"32","author":"Dunogue","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2014.08.002_bb0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","article-title":"Churg\u2013Strauss syndrome. Clinical study and long-term follow-up of 96 patients","volume":"78","author":"Guillevin","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2014.08.002_bb0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.lpm.2013.02.308","article-title":"L5. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss)","volume":"42","author":"Cordier","year":"2013","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2014.08.002_bb0140","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1136\/annrheumdis-2013-204831","article-title":"Response to: \u2018Five-factor score in patients with eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss; EGPA): to use or not to use?\u2019 by Moiseev and Novikov","volume":"73","author":"Samson","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.002_bb0145","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/rheumatology\/36.12.1290","article-title":"Treatment of good-prognosis polyarteritis nodosa and Churg\u2013Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides","volume":"36","author":"Gayraud","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.002_bb0150","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/0895-4356(95)00510-2","article-title":"Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy","volume":"48","author":"Concato","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.autrev.2014.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","article-title":"Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates","volume":"48","author":"Peduzzi","year":"1995","journal-title":"J Clin Epidemiol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T12:56:33Z","timestamp":1538312193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214001451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1568997214001451"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}